GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
Germany will be the first launch market
Germany will be the first launch market
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
Over 8.8?million Indians aged 60 and above currently live with dementia,
Subscribe To Our Newsletter & Stay Updated